Agenus Inc.
NASDAQ:AGENBiotechnology
-$0.01 today
- Market cap
- $289.58M
- Beta
- 1.54
- P/E (TTM)
- 1.7
- EPS (TTM)
- $1.70
Volume 0.88M
Average 0.82M
AGEN Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Agenus Inc.NASDAQ: AGEN
Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Investing cash flow growth accelerates
Q1 FY2026 investing cash flow of $68.95M rose 120868.4% year over year, ahead of the +48437.2% change in trailing-twelve-month investing cash flow. Sequentially, it rose 8740.0% from the prior quarter.
Context
- Investing cash flow amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Investing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +120868.4% holds above the trailing-twelve-month pace of +48437.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 27K USD
- Year-over-year change
- +0.0%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 27K | +0.0% |
| FY2024 | 2024-12-31 | 27K | -99.2% |
| FY2023 | 2023-12-31 | 3.4M | +110.1% |
| FY2022 | 2022-12-31 | (33.61M) | +22.1% |
| FY2021 | 2021-12-31 | (43.15M) | — |
Investing Cash Flow vs competitors
How AGEN compares with its peers on the latest reported figures
- AGEN's LTM Mar 2026 investing cash flow of $70.09M is the 4th largest of the 10 companies compared; the peer median is $55.01M.
- Its year-over-year change of +48437.2% is the highest of 8, against a peer median of -22.1%.
- Investing cash flow amounts to 56.6% of revenue for AGEN, versus a peer median of 365.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $121.16M | -22.1% | — | — | |
| LTM Mar 2026 | $92.08M | +145.0% | -12.6% | 1457.9% | |
| LTM Mar 2026 | $91.44M | +6.4% | +50.6% | — | |
| LTM Mar 2026 | $70.09M | +48437.2% | — | 56.6% | |
| LTM Mar 2026 | $61.08M | -59.3% | — | — | |
| LTM Mar 2026 | $55.01M | -5.3% | — | 365.8% | |
| LTM Mar 2026 | $16.73M | -71.5% | -49.6% | — | |
| LTM Mar 2026 | $233.16K | — | +232.7% | — | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $165.21K | — | — | — |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $0 | -100.0% | — | 0.0% |
| Peer median (excluding AGEN) | $55.01M | -22.1% | +19.0% | 365.8% | |
Competitors are the stored peer set for AGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (28.72M) | (230.66M) | (257.44M) | (232.27M) | (232.27M) |
| Depreciation & Amortization | 6.79M | 6.95M | 13.59M | 13.34M | 13.34M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 19.58M | 18.34M | 22.87M | 17.39M | 17.39M |
| Change in Working Capital | (9.74M) | 24.08M | 10.76M | 32.6M | 27.33M |
| Accounts Receivables | (394K) | 122K | (23.46M) | 25.34M | (1.73M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 10.82M | 6.49M | 21.37M | 2.01M | 23.5M |
| Other Working Capital | (20.17M) | 17.47M | 12.85M | 5.25M | 5.56M |
| Other Non-Cash Items | 22.25M | 5.92M | (13.98M) | 10.62M | 15.89M |
| Operating Cash Flow | 10.15M | (175.37M) | (224.2M) | (158.32M) | (158.32M) |
| Capital Expenditures | (33.81M) | (53.06M) | (9.95M) | (576K) | (576K) |
| Acquisitions (Net) | 0 | (2.92M) | 0 | 0 | 0 |
| Purchases of Investments | (14.99M) | (24.63M) | (20.04M) | 0 | 0 |
| Sales of Investments | 0 | 25M | 30.03M | 579K | 579K |
| Other Investing Activities | 5.66M | 22M | 3.36M | 24K | 24K |
| Investing Cash Flow | (43.15M) | (33.61M) | 3.4M | 27K | 27K |
| Debt Repayment | (1.32M) | (490K) | (8.93M) | 9.52M | 2.35M |
| Common Stock Issued | 220.65M | 99.21M | 133.16M | 38.82M | 36.31M |
| Common Stock Repurchased | (1.65M) | (3.79M) | (5.17M) | 0 | (87K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 7.59M | 898K | 807K | 74.5M | 84.27M |
| Financing Cash Flow | 225.26M | 95.83M | 119.87M | 122.84M | 122.84M |
| Effect of Forex Changes | (164K) | (104K) | (628K) | (260K) | (260K) |
| Net Change in Cash | 192.1M | (113.26M) | (101.56M) | (35.71M) | (35.71M) |
| Free Cash Flow | (23.67M) | (228.44M) | (234.16M) | (158.89M) | (158.89M) |
Agenus Inc.
NASDAQ:AGEN
Intrinsic Alpha fair value
Locked
Current Price
$6.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.